NTLA Intellia Therapeutics Inc

Price (delayed)

$137.71

Market cap

$9.39B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.47

Enterprise value

$9.32B

Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. ...

Highlights
Intellia Therapeutics's equity has soared by 120% YoY and by 3.6% from the previous quarter
The company's quick ratio rose by 29% YoY and by 3.3% QoQ
Intellia Therapeutics's revenue has increased by 13% YoY but it has decreased by 11% QoQ
The gross profit has grown by 13% YoY but it has contracted by 11% from the previous quarter
The company's debt has surged by 199% YoY and by 85% QoQ
The net income has contracted by 36% YoY and by 11% from the previous quarter

Key stats

What are the main financial stats of NTLA
Market
Shares outstanding
68.15M
Market cap
$9.39B
Enterprise value
$9.32B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
17.09
Price to sales (P/S)
179.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
180.82
Earnings
Revenue
$51.52M
EBIT
-$148.63M
EBITDA
-$142.27M
Free cash flow
-$68.9M
Per share
EPS
-$2.47
Free cash flow per share
-$1.03
Book value per share
$8.06
Revenue per share
$0.77
TBVPS
$10.67
Balance sheet
Total assets
$716.89M
Total liabilities
$171.02M
Debt
$72.74M
Equity
$545.87M
Working capital
$540.38M
Liquidity
Debt to equity
0.13
Current ratio
9.9
Quick ratio
9.64
Net debt/EBITDA
0.48
Margins
EBITDA margin
-276.1%
Gross margin
100%
Net margin
-288.5%
Operating margin
-291.1%
Efficiency
Return on assets
-25.4%
Return on equity
-33.9%
Return on invested capital
-42%
Return on capital employed
-22.7%
Return on sales
-288.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NTLA stock price

How has the Intellia Therapeutics stock price performed over time
Intraday
-6.88%
1 week
1.82%
1 month
64.74%
1 year
600.81%
YTD
153.14%
QTD
-14.95%

Financial performance

How have Intellia Therapeutics's revenue and profit performed over time
Revenue
$51.52M
Gross profit
$51.52M
Operating income
-$149.96M
Net income
-$148.63M
Gross margin
100%
Net margin
-288.5%
The net income has contracted by 36% YoY and by 11% from the previous quarter
The company's operating income fell by 30% YoY and by 10% QoQ
The company's net margin fell by 25% QoQ and by 20% YoY
Intellia Therapeutics's operating margin has decreased by 24% QoQ and by 15% YoY

Growth

What is Intellia Therapeutics's growth rate over time

Valuation

What is Intellia Therapeutics stock price valuation
P/E
N/A
P/B
17.09
P/S
179.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
180.82
The EPS has contracted by 9% YoY and by 2.9% from the previous quarter
The stock's P/B is 200% above its last 4 quarters average of 5.7
Intellia Therapeutics's equity has soared by 120% YoY and by 3.6% from the previous quarter
Intellia Therapeutics's revenue has increased by 13% YoY but it has decreased by 11% QoQ

Efficiency

How efficient is Intellia Therapeutics business performance
The ROS has contracted by 25% from the previous quarter and by 20% YoY
The ROA has grown by 22% YoY and by 8% from the previous quarter
Intellia Therapeutics's ROIC has increased by 18% from the previous quarter
Intellia Therapeutics's ROE has increased by 17% YoY and by 8% from the previous quarter

Dividends

What is NTLA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NTLA.

Financial health

How did Intellia Therapeutics financials performed over time
Intellia Therapeutics's total liabilities has surged by 155% YoY and by 15% QoQ
The total assets has soared by 128% YoY and by 6% from the previous quarter
The company's debt is 87% lower than its equity
The company's debt has surged by 199% YoY and by 85% QoQ
Intellia Therapeutics's equity has soared by 120% YoY and by 3.6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.